Cg Oncology, Inc. · NASDAQ:CGON
Cg Oncology — New England Section of the American Urological Association Annual Meeting 2026
12 slides from Cg Oncology's conference presentation, Oct 23, 2026
Slide 1: Durable 24-Month Outcomes From BOND-003 Cohort C
Durable 24-Month Outcomes From BOND-003 Cohort C PHASE 3 STUDY OF INTRAVESICAL CRETOSTIMOGENE GRENADENOREPVEC FOR HIGH- RISK BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU Mark A. Preston, MD, MPH For individual reference only. The information Presented at the New England
Slide 2: Disclosures
Disclosures • Clinical trial investigator: CG Oncology, Inc. 2
Slide 3: Oncolytic Immunotherapy: Cretostimogene Grenadenorepvec's Dual Mechanism of Action
Oncolytic Immunotherapy: Cretostimogene Grenadenorepvec’s Dual Mechanism of Action 3
Slide 4: BOND-003 Cohort C: Phase 3 Cretostimogene Monotherapy Study Design
BOND-003 COHORT C: Phase 3 Cretostimogene Monotherapy for High- Risk BCG-Unresponsive NMIBC with CIS Cretostimogene Grenadenorepvec Primary Endpoint: HR BCG-Unresponsive NMIBC Single-Arm, Open-Label, IVE Administration CR at Any Time POPULATION STUDY DESIGN / REGIMEN ADDITIONAL ENDPOINTS • Enrollmen
Slide 5: Patient Demographics & Baseline Characteristics
5 Patient Demographics & Baseline Characteristics Subjects in Safety Dataset N=112 % Gender Male 83 74.1 • Majority of patients are: Female 29 25.9 Age (Years) • Male (74%) Mean (SD) 72.9 (9.19) • White (62%) Median (Range) 74.0 (43-90) Age (Categories) • > 65 years (83%) < 65 19 17.0 • 63.4% of pat
Slide 6: Overall CR Rate At Any Time
6 Consistent, Compelling Efficacy & Safety 100 75.5% CR Landmark CR Rate, % (95% CI) CR by K-M Est (95% CI) 95% CI, 66.3 - 83.2 Overall CR Rate At Any Time (%) 12-month 46.4% (36.8, 56.1) 50.7% (40.9, 59.8) 75 51/110 patients 41.8% (32.5, 51.6) 24-month1 42.4% (32.7, 51.7) 46/110 patients 50 CR (n=8
Slide 7: Consistent, Favorable and Well-Tolerated Safety Profile
7 Consistent, Favorable and Well-Tolerated Safety Profile Preferred Term Cretostimogene (n=112) (MedDRA v.26.1) Grade ≥ 3 • Most AEs were Grade 1-2 Any Grade (%) Patients with ≥ 1 • 0% Grade ≥ 3 TRAEs or deaths 71 (63.4%) 0 (0) TRAE • Median time to TRAE Treatment-Related AE reported in > 10% patien
Slide 8: Key Takeaways
Key Takeaways • Cretostimogene grenadenorepvec provides compelling CR rate (75.5%) • Durable responses • Median DoR not reached but exceeds 28 months • 90% of 12-month responders sustained durable outcomes at Year 2 • Very well-tolerated regimen • No grade 3+ TRAE or discontinuations • 97.3% complet
Slide 9: Thank You
9 THANK YOU Click to edit Master title style All Bladder Cancer Patients and Their Families Key Investigators, Study Coordinators, Nurses Mark Tyson, AZ, USA Donald Lamm, AZ, USA Roger Li, FL, USA Lambros Stamatakis, MD, USA Jong-Kil Nam, S. Korea Hong Koo Ha, Busan, S. Korea Shreyas Joshi, GA, USA
Slide 10: Cretostimogene Demonstrates Durable Responses in HR BCG-UR NMIBC
10 Cretostimogene Demonstrates Durable Responses in HR BCG-UR NMIBC Estimated DOR Probability at 12 Months Estimated DOR Probability Duration of Response Probability (%) 64.2% at 24 Months (95% CI: 52.2-73.8) 60.1% (95% CI: 48.2-70.0) • Median DoR is 27.9 months and ongoing (95% CI 14.3-NE) • Median
Slide 11: Sustained Responses Observed over Months
11 Sustained Responses Observed over 45 Months Patients with CR (N=83) • 50.0% of patients reinduced with oncolytic immunotherapy converted to CR1 • 64.3% remain in durable response after conversion to CR • Patients remain in response after treatment completion Time in Months from First Treatment BC
Slide 12: High CR Rate Consistent Across Patient Subgroups, Including Prior Chemotherapy
12 High CR Rate Consistent Across Patient Subgroups, Including Patients Treated with Prior Chemotherapy BCG: Bacillus Calmette-Guérin; CI: confidence interval; CIS: carcinoma in situ; CR: complete response; HG: high grade; Ta/T1: papillary tumor stages Ta and T1 Complete Response Rate (95% CI) 12
CG Oncology — New England Section of the American Urological Association Annual Meeting 2026 on 6ix